LT3675854T - Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti - Google Patents

Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti

Info

Publication number: LT3675854T
Authority: LT; Lithuania
Prior art keywords: glomerulopathy; piperidinyl; treatment; indole derivatives; indole
Prior art date: 2017-08-31

Application number

LTEPPCT/IB2018/056618T

Other languages

English (en)

Inventor

Jörg EDER

Richard Alexander Harrison

Boerje Haraldsson

Anna Svenja Schubart

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-31

Filing date

2018-08-30

Publication date

2025-04-25

2018-08-30 Application filed by Novartis Ag filed Critical Novartis Ag

2025-04-25 Publication of LT3675854T publication Critical patent/LT3675854T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LTEPPCT/IB2018/056618T 2017-08-31 2018-08-30 Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti LT3675854T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17188870		2017-08-31
PCT/IB2018/056618 WO2019043609A1 (en)	2017-08-31	2018-08-30	NEW USES OF PIPERIDINYL-INDOLE DERIVATIVES

Publications (1)

Publication Number	Publication Date
LT3675854T true LT3675854T (lt)	2025-04-25

Family

ID=59745840

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP24170648.0T LT4393545T (lt)	2017-08-31	2018-08-30	Nauji piperidinilindolo darinių naudojimo būdai
LTEPPCT/IB2018/056618T LT3675854T (lt)	2017-08-31	2018-08-30	Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP24170648.0T LT4393545T (lt)	2017-08-31	2018-08-30	Nauji piperidinilindolo darinių naudojimo būdai

Country Status (22)

Country	Link
US (3)	US11723901B2 (lt)
EP (3)	EP4647121A3 (lt)
JP (3)	JP6754919B1 (lt)
KR (3)	KR102682887B1 (lt)
CN (5)	CN117398384A (lt)
AU (1)	AU2018326768B2 (lt)
BR (1)	BR112020003737A2 (lt)
CA (1)	CA3073346A1 (lt)
CL (1)	CL2020000483A1 (lt)
DK (2)	DK4393545T3 (lt)
ES (1)	ES3022885T3 (lt)
FI (2)	FI3675854T3 (lt)
HR (2)	HRP20251596T1 (lt)
HU (1)	HUE071118T2 (lt)
IL (1)	IL272888B2 (lt)
LT (2)	LT4393545T (lt)
MX (3)	MX2020002185A (lt)
PL (1)	PL3675854T3 (lt)
PT (2)	PT4393545T (lt)
RS (2)	RS67530B1 (lt)
SI (1)	SI3675854T1 (lt)
WO (1)	WO2019043609A1 (lt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI3675854T3 (fi)	2017-08-31	2025-04-07	Novartis Ag	Piperidinyyli-indolijohdannaisia käytettäväksi c3-glomerulopatian hoidossa
WO2021125313A1 (ja) *	2019-12-19	2021-06-24	大鵬薬品工業株式会社	縮合ピリミジン化合物を有効成分とする治療剤
EP4153580A1 (en)	2020-05-18	2023-03-29	Novartis AG	Crystalline form of lnp023
KR20230049115A (ko) *	2020-08-07	2023-04-12	상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드	보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
WO2022028507A1 (zh)	2020-08-07	2022-02-10	上海美悦生物科技发展有限公司	一种杂环类化合物、其制备方法及用途
CN119798258A (zh)	2020-12-30	2025-04-11	江苏恒瑞医药股份有限公司	含氮桥杂环化合物、其制备方法及其在医药上的应用
CA3203447A1 (en) *	2020-12-30	2022-07-07	Kevin X Chen	Series of piperidine-substituted benzoic acid compounds, and use thereof
JP2024517234A (ja) *	2021-05-07	2024-04-19	ノバルティスアーゲー	非典型溶血性尿毒症症候群の処置のためのイプタコパン
AU2022329230A1 (en) *	2021-08-18	2024-03-21	Xizang Haisco Pharmaceutical Co., Ltd.	Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
TW202334121A (zh) *	2021-10-27	2023-09-01	美商翰森生物有限責任公司	哌啶基吲哚衍生物、其製備方法及醫藥用途
AU2023209631A1 (en) *	2022-01-24	2024-07-25	Novartis Ag	Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof
AU2023210941A1 (en) *	2022-01-26	2024-07-11	Shanghai Meiyue Biotech Development Co., Ltd.	Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
WO2023237041A1 (zh) *	2022-06-10	2023-12-14	正大天晴药业集团股份有限公司	双环取代的芳香羧酸酯类化合物
CN119698414A (zh) *	2022-06-20	2025-03-25	深圳信立泰药业股份有限公司	一种吲哚-苯基哌啶化合物及其制备方法与应用
CA3260069A1 (en) *	2022-06-30	2025-04-01	Shanghai Hengrui Pharmaceutical Co., Ltd.	Pharmaceutically acceptable salt and crystalline form of nitrogen-bridged heterocyclic derivative, and their method of preparation
JP2025530222A (ja) *	2022-09-10	2025-09-11	江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司	２－置換ピペリジン誘導体、その製造方法及び医薬的用途
KR20250103768A (ko)	2022-11-11	2025-07-07	상하이 이셩 바이오파마슈티컬 컴퍼니 리미티드	피리딘 치환 벤조산계 화합물, 이의 약학 조성물 및 용도
CN120435467A (zh) *	2022-12-31	2025-08-05	珠海联邦制药股份有限公司	补体因子b抑制剂及其药物组合物和应用
WO2025021158A1 (zh) *	2023-07-26	2025-01-30	上海美悦生物科技发展有限公司	螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8192742B2 (en) *	2007-03-23	2012-06-05	NovelMed Therapeutics	Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
US9487483B2 (en)	2012-06-28	2016-11-08	Novartis Ag	Complement pathway modulators and uses thereof
CN105229003B (zh) *	2013-03-14	2017-03-15	诺华股份有限公司	作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物
JO3425B1 (ar) *	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
CN108699121B (zh)	2015-12-23	2023-07-04	艾丽法有限责任公司	用于抑制补体激活的多肽
KR102528260B1 (ko) *	2016-01-05	2023-05-04	유니버시티 오브 레스터	필요로 하는 대상체에서 섬유증의 억제 방법
FI3675854T3 (fi)	2017-08-31	2025-04-07	Novartis Ag	Piperidinyyli-indolijohdannaisia käytettäväksi c3-glomerulopatian hoidossa
EP4153580A1 (en)	2020-05-18	2023-03-29	Novartis AG	Crystalline form of lnp023
US11951101B2 (en)	2020-07-16	2024-04-09	Novartis Ag	Methods of using factor B inhibitors

2018
- 2018-08-30 FI FIEP18769510.1T patent/FI3675854T3/fi active
- 2018-08-30 MX MX2020002185A patent/MX2020002185A/es unknown
- 2018-08-30 EP EP25198507.3A patent/EP4647121A3/en active Pending
- 2018-08-30 EP EP18769510.1A patent/EP3675854B1/en active Active
- 2018-08-30 WO PCT/IB2018/056618 patent/WO2019043609A1/en not_active Ceased
- 2018-08-30 JP JP2020511476A patent/JP6754919B1/ja active Active
- 2018-08-30 KR KR1020237003993A patent/KR102682887B1/ko active Active
- 2018-08-30 BR BR112020003737-0A patent/BR112020003737A2/pt not_active Application Discontinuation
- 2018-08-30 CN CN202311580827.XA patent/CN117398384A/zh active Pending
- 2018-08-30 ES ES18769510T patent/ES3022885T3/es active Active
- 2018-08-30 DK DK24170648.0T patent/DK4393545T3/da active
- 2018-08-30 HR HRP20251596TT patent/HRP20251596T1/hr unknown
- 2018-08-30 CA CA3073346A patent/CA3073346A1/en active Pending
- 2018-08-30 FI FIEP24170648.0T patent/FI4393545T3/fi active
- 2018-08-30 HU HUE18769510A patent/HUE071118T2/hu unknown
- 2018-08-30 HR HRP20250386TT patent/HRP20250386T1/hr unknown
- 2018-08-30 LT LTEP24170648.0T patent/LT4393545T/lt unknown
- 2018-08-30 LT LTEPPCT/IB2018/056618T patent/LT3675854T/lt unknown
- 2018-08-30 KR KR1020207005594A patent/KR102497487B1/ko active Active
- 2018-08-30 KR KR1020247022322A patent/KR20240111007A/ko active Pending
- 2018-08-30 SI SI201831224T patent/SI3675854T1/sl unknown
- 2018-08-30 DK DK18769510.1T patent/DK3675854T3/da active
- 2018-08-30 CN CN202311580742.1A patent/CN117338782A/zh active Pending
- 2018-08-30 CN CN202311580686.1A patent/CN117338781A/zh active Pending
- 2018-08-30 US US16/642,905 patent/US11723901B2/en active Active
- 2018-08-30 RS RS20251274A patent/RS67530B1/sr unknown
- 2018-08-30 PT PT241706480T patent/PT4393545T/pt unknown
- 2018-08-30 RS RS20250315A patent/RS66635B1/sr unknown
- 2018-08-30 IL IL272888A patent/IL272888B2/en unknown
- 2018-08-30 PL PL18769510.1T patent/PL3675854T3/pl unknown
- 2018-08-30 CN CN201880052545.3A patent/CN111032042A/zh active Pending
- 2018-08-30 AU AU2018326768A patent/AU2018326768B2/en active Active
- 2018-08-30 EP EP24170648.0A patent/EP4393545B1/en active Active
- 2018-08-30 CN CN202311580786.4A patent/CN117338783A/zh active Pending
- 2018-08-30 PT PT187695101T patent/PT3675854T/pt unknown
2020
- 2020-02-26 MX MX2023010751A patent/MX2023010751A/es unknown
- 2020-02-26 MX MX2023010750A patent/MX2023010750A/es unknown
- 2020-02-27 CL CL2020000483A patent/CL2020000483A1/es unknown
- 2020-08-24 JP JP2020140744A patent/JP6929425B2/ja active Active
2021
- 2021-08-10 JP JP2021130445A patent/JP7297016B2/ja active Active
2022
- 2022-01-31 US US17/589,281 patent/US12285422B2/en active Active
2024
- 2024-11-06 US US18/938,560 patent/US20250195493A1/en active Pending

Also Published As

Publication number	Publication date
AU2018326768B2 (en)	2021-07-29
EP4393545A3 (en)	2024-09-25
MX2020002185A (es)	2020-07-14
FI4393545T3 (fi)	2026-01-14
EP4647121A3 (en)	2026-02-18
DK3675854T3 (da)	2025-04-07
US20220152011A1 (en)	2022-05-19
KR102682887B1 (ko)	2024-07-08
CL2020000483A1 (es)	2020-09-04
JP6929425B2 (ja)	2021-09-01
PT3675854T (pt)	2025-04-04
JP2020193222A (ja)	2020-12-03
US20250195493A1 (en)	2025-06-19
EP4393545A2 (en)	2024-07-03
JP2021181471A (ja)	2021-11-25
KR20200047540A (ko)	2020-05-07
KR20240111007A (ko)	2024-07-16
KR102497487B1 (ko)	2023-02-08
CN117338783A (zh)	2024-01-05
BR112020003737A2 (pt)	2020-09-01
CA3073346A1 (en)	2019-03-07
JP2020529466A (ja)	2020-10-08
US20200338059A1 (en)	2020-10-29
PT4393545T (pt)	2025-12-23
RU2020111788A3 (lt)	2021-12-28
LT4393545T (lt)	2026-01-12
US12285422B2 (en)	2025-04-29
EP3675854A1 (en)	2020-07-08
CN111032042A (zh)	2020-04-17
US11723901B2 (en)	2023-08-15
SI3675854T1 (sl)	2025-05-30
AU2018326768A1 (en)	2020-02-06
PL3675854T3 (pl)	2025-05-19
FI3675854T3 (fi)	2025-04-07
JP6754919B1 (ja)	2020-09-16
HRP20250386T1 (hr)	2025-05-23
MX2023010751A (es)	2023-09-20
MX2023010750A (es)	2023-09-20
RS67530B1 (sr)	2026-01-30
EP4647121A2 (en)	2025-11-12
RU2020111788A (ru)	2021-09-30
DK4393545T3 (da)	2026-01-12
IL272888B2 (en)	2024-01-01
EP4393545B1 (en)	2025-10-08
CN117338781A (zh)	2024-01-05
IL272888B1 (en)	2023-09-01
KR20230024432A (ko)	2023-02-20
RS66635B1 (sr)	2025-04-30
HUE071118T2 (hu)	2025-08-28
CN117338782A (zh)	2024-01-05
CN117398384A (zh)	2024-01-16
WO2019043609A1 (en)	2019-03-07
ES3022885T3 (en)	2025-05-29
IL272888A (en)	2020-04-30
HRP20251596T1 (hr)	2026-01-30
JP7297016B2 (ja)	2023-06-23
EP3675854B1 (en)	2025-01-22

Publication	Publication Date	Title
LT3675854T (lt)	2025-04-25	Piperidinilindolo dariniai, skirti c3 glomerulopatijai gydyti
ZA201803742B (en)	2020-08-26	Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
ZA201607415B (en)	2019-06-26	Antibody-drug-conjugate and its use for the treatment of cancer
IL276733A (en)	2020-09-30	Use of Aribolin in cancer treatment
ZA201807810B (en)	2021-04-28	Adenosine derivatives for use in the treatment of cancer
IL248767B (en)	2021-08-31	Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
PT3331610T (pt)	2021-05-07	Agentes para utilização no tratamento de glioma
GB201617064D0 (en)	2016-11-23	Compounds and their therapeutic use
GB2538923B (en)	2020-03-25	A therapeutic agent for use in the treatment of infections
IL246855A0 (en)	2016-08-31	Materials for use in the treatment of retinitis
PL3675879T3 (pl)	2022-02-14	Cerebrolizyna do zastosowania w leczeniu cadasil
IL253933A0 (en)	2017-10-31	History of pyrimidine use in the treatment of cancer
ZA202006886B (en)	2022-07-27	R-fadrozole for use in the treatment of aldostonerism
IL269121A (en)	2019-11-28	Usl-311 for use in the treatment of cancer
PT3049085T (pt)	2021-10-01	Inibidores de sgk1 no tratamento da síndrome do qt longo
LT3548006T (lt)	2024-01-10	Kompozicija, skirta žarnyno pakitimams gydyti
PL3341481T3 (pl)	2021-12-13	Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne
PT3370727T (pt)	2022-04-18	Derivados da pregnenolona substituídos em c3 não bioconvertíveis para utilização no tratamento de distúrbios de toxicodependência
HK1248110A1 (en)	2018-10-12	Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases